Subject: BICX CEO Outlines Productive 2018 and Positive Outlook for 2019

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
BICX CEO Outlines Productive 2018 and Positive Outlook for 2019
Hot Stock to WatchHot Stock to Watch

Company: BioCorRx Inc. (OTCQB: BICX)


Price: 0.078

Change (%): - 0.002 (2.5)

Volume: 12,500

Brady Granier, CEO, President, and Director of BioCorRx Inc. Provides Update and Outlook in a New Audio Interview with

AUSTIN, Texas, Dec. 12, 2018 (GLOBE NEWSWIRE) -, Inc. (SCV) and BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that a new audio interview with the Company is now available.

The interview featuring an overview of BICX’s current news and moves can be heard at

Brady Granier called in to, Inc. to discuss the progress the Company has made in several key areas, the operational outlook for 2019, the launch of a new weight loss program and more. BioCorRx, Inc. issued a third quarter business update in November outlining where the Company stands with NIDA on their grant application process. In addition, the Company has been working diligently to advance all of its programs in the fight against addiction and specifically the fight against the opioid crisis.

In the interview Granier stated, “Right now, the big focus for the Company is our FDA approval pathway for BICX102, which is our naltrexone implant. We have been working in the naltrexone implant space for many years and that hasn’t changed. What has changed is that now we are seeking FDA approval on one of our naltrexone implants.” In terms of the NIDA (National Institute on Drug Abuse) grant application for BICX102, Granier updated the listeners, “Our grant was reviewed in August and September (2018) and we were recommended for funding by the independent scientific review board. Now the grant is pending for administrative review. We have received a favorable score on our grant as well. We remain confident on the prospect of getting the grant.”

Continue Reading

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks